Shivalik Rasayan Ltd

Resolutions proposed

• Special Resolution: Issuance of up to 3,72,000 equity shares to public on a preferential basis.
• Special Resolution: Issuance of up to 9,48,000 fully convertible warrants to promoter group and public on a preferential basis.

Voting status

• Voting results not announced; Scrutinizer report to determine approval.

Shareholding impact

• Impact on shareholding will depend on allotment; no final percentages disclosed.

Other notes

• EGM held Aug 20, 2026; meeting details and scrutinizer appointed for e-voting.

Shareholding / Insider Disclosure

• Former director Sanjay Bansal sold 25,000 equity shares on the open market.
• Pre-disposal holdings were 50,000 shares (0.32%), post-disposal holdings 25,000 shares (0.16%).
• Trade date: 21 August 2026; sale value: Rs 6,831,455.
• On-market sale; exchanges: NSE and BSE.

Resolution 1: Equity issue

• Special resolution to issue up to 3,72,000 equity shares to Public on a preferential basis; approved.

Resolution 2: Warrants issue

• Special resolution to issue up to 9,48,000 fully convertible warrants to promoter group and Public; approved.

Resolutions

• Resolution 1: Special; up to 3,72,000 equity shares to Public on preferential basis.
• Resolution 2: Special; up to 9,48,000 Fully Convertible Warrants to Promoter Group and Public on preferential basis.

Voting outcomes

• Resolution 1 approved; 99.9994% in favour, 0.0006% against.
• Resolution 2 approved; 99.999% in favour, 0.001% against.

Promoter participation

• Resolution 1 promoter interest: No.
• Resolution 2 promoter interest: Yes.

Resolutions

• Special Resolution: Issuance of up to 3,72,000 Equity Shares to public on a preferential basis.
• Special Resolution: Issuance of up to 9,48,000 Fully Convertible Warrants to promoter/promoter group and public on preferential basis.
• Promoter/director interest: not disclosed.
• Voting outcome: not available; results to be provided after Scrutinizer's report.
• Impact on shareholding: not determinable yet.
• Use of proceeds: not disclosed.
• Board/management changes: none disclosed.

Overview

• Standalone BRSR for FY2025-26 filed by Shivalik Rasayan Limited.
• Turnover mix: Agrochemicals 88.85%, Pharma API 5.31%, R&D 5.83%.
• FY-end date is 31 March 2026; standalone report, no external assurance.

Governance and group structure

• Holding: Growel Remedies Ltd 47.37%; Associate: Medicamen Biotech Ltd 40.46%.
• Related-party transactions: Purchases 7.49%; Sales 1,345.40%; Investments 8,109.13.
• ABAC policy exists with whistleblower mechanism; policy link on company website.

ESG and environmental metrics

• ESG certifications: ISO 9001:2015; ISO 14001:2015; ISO 45001:2018.
• ZLD in-house: ETP, RO, MEE, STP facilities.
• Total waste 16.38 MT; hazardous waste 16.08 MT; ETP sludge 16.08 MT.

Dividend record date details

• Dividend, if approved, will be paid from Oct 15, 2026 to shareholders on record Sept 21, 2026.
• Beneficial owners in electronic form will be paid per depository data by Sept 21, 2026.
• Physical form holders registered by close of business Sept 21, 2026 will receive dividend.
• Dividend payment is subject to tax deduction at source.
• Security: equity shares.

Financial results

• Un-audited standalone and consolidated results for quarter ended 30-06-2026 approved.
• Unaudited segment-wise revenue, results, assets and liabilities for quarter ended 30-06-2026 approved.
• Audit Committee reviewed the unaudited results prior to Board approval.

Annual report and AGM

• Draft Annual Report for FY 2025-26 approved.
• AGM scheduled September 28, 2026, at 1:00 PM, Dehradun.
• Cut-off date for electronic voting fixed September 21, 2026.
• Electronic voting window September 25-27, 2026.
• Register of Members and transfer books closed Sep 22-28, 2026.
• Final dividend proposed at 10% or Rs 0.50 per share, subject to AGM approval.

Associate disclosure and auditor remarks

• Consolidated results include Medicamen Biotech Limited as associate.
• Limited Review Reports on standalone and consolidated results found no material misstatement.

Filing Status

• Board approves Audited Standalone and Consolidated Financial Results for year ended 31 March 2026.
• Final dividend recommended at 10% (Rs 5 share), i.e. ₹0.50 per equity share, subject to AGM.
• Results will be available on the company website.

Governance Changes

• Sanjay Bansal resigns as Non-Executive Director.
• Internal Auditor appointed: Arun Agarwal & Co for 2026-27.
• Cost Auditor appointed: Cheena & Associates for 2026-27.
• Committees reconstituted: Audit, Stakeholders Relationship, Nomination & Remuneration, and Risk Management.

Clarifications / Compliance

• NSE observation on balancing figure note resolved; revised results annexed.
• Auditors' report issued with unmodified opinion (standalone and consolidated).
• Declaration under Regulation 33(3)(d) of SEBI LODR: unmodified opinion.
• Results to be hosted on www.shivalikrasayan.com.